Skip to main content
Medical Reference · Condition Monograph

Multiple Sclerosis

다발성경화증

A chronic neurological disease in which the immune system attacks the myelin sheath that surrounds the nerves. Because symptoms appear in varied forms and repeatedly relapse and remit, early diagnosis and consistent treatment are important for the course of the disease.

History

Multiple sclerosis (MS) is a disease in which inflammation and scarring develop in multiple places in the central nervous system, such as the brain and spinal cord, so that neurological symptoms that differ in timing and location can recur. In the 1800s there were records of multiple "spot-like scars" in the brain and spinal cord observed at autopsy, and the present concept became established when Jean-Martin Charcot, in 1868, grouped the symptoms and pathological findings of similar patients and defined them as a single independent disease. At that time, features such as the patient's tremor, nystagmus, and speech that sounded broken up were emphasized, but over time it became known that this "classic triad" appears in only some patients.

Until the mid-20th century, clinical symptoms and observation of the disease course were central, and it was difficult to distinguish MS from other neurological diseases. After the 1980s, as magnetic resonance imaging (MRI) technology came into wide use, lesions in the brain and spinal cord could be seen even before symptoms appeared or when symptoms were mild, and diagnosis became faster. In addition, as tests confirming traces of an immune response in the cerebrospinal fluid became established, diagnostic accuracy improved.

Treatment changed greatly from the 1990s with the emergence of "disease-modifying therapy," which slows relapses and progression of the disease. Initially injectable treatments were central, but the options later expanded to include oral medications and antibody therapies, and the effect of reducing relapses generally improved as well. In recent research, treatment strategies continue to be updated in the direction that making the diagnosis earlier and treating actively from the early stage can reduce the rate at which disability accumulates over the long term.

Causes

The cause is difficult to pin down to a single factor, and it helps to understand that several factors overlap to create a situation in which the immune system mistakenly recognizes the nerves as "foreign invaders." In other words, it is thought that the immune system, the body's defense system, attacks the myelin, which acts as insulation for the brain and spinal cord, creating inflammation, and as a result nerve signal transmission slows or is interrupted, causing symptoms.

Environmental factors that have repeatedly been cited include sunlight exposure from childhood and vitamin D levels, smoking, adolescent obesity, and certain infections (especially Epstein-Barr virus). Recent research presents both epidemiological evidence that Epstein-Barr virus is very strongly linked to the development of multiple sclerosis and a mechanistic explanation that the immune response can confuse viral proteins with nerve components and react excessively.

However, this does not mean that "everyone infected with the virus develops multiple sclerosis." Most people are exposed to Epstein-Barr virus, but multiple sclerosis develops in only a few. Therefore, research continues on how genetic predisposition, lifestyle, and other environmental factors cause the immune balance to break down "in certain people."

Genetic Epidemiology

Rather than a single-gene disease with a clear family history, multiple sclerosis is more accurately understood as a condition in which multiple genetic variants each raise the risk "a little." The best known is the HLA gene region, which determines the direction of the immune response; the risk can increase when a person has certain HLA types. This genetic predisposition is close to a default setting that determines "what the immune system reacts strongly to and what it tolerates."

If a family member has the disease, the risk is higher than average, but the absolute risk does not become very high. For example, even in identical twins, if one has multiple sclerosis, the probability that the other will also develop it rises "considerably," but it does not reach 100%. This is also indirect evidence that the disease is not determined by genetics alone and that environmental factors play a large role.

In recent research, there are increasing attempts to estimate risk by "adding up multiple genetic variants" using concepts such as a genetic risk score. However, there are still limitations to using it as a tool accurate enough to predict onset or future course at the individual level. Therefore, in clinical practice, rather than diagnosing multiple sclerosis or determining prognosis with a specific genetic test alone, an approach that judges by combining the clinical picture, imaging, and test findings is still the standard.

General Epidemiology

Multiple sclerosis generally often begins in a person's 20s to 40s and is more common in women. Prevalence varies greatly by country and region, and a "latitude gradient," in which it is traditionally more common farther from the equator (in high-latitude regions), is well known. Sunlight (ultraviolet) exposure and vitamin D, lifestyle, and the genetic background of population groups are presumed to contribute to this difference.

Recent studies report a trend of increasing numbers of multiple sclerosis patients worldwide. This may be because actual incidence has increased, but it may also reflect better detection than before due to improved access to MRI and more refined diagnostic criteria. The effect of increasing prevalence as survival lengthens with better treatment outcomes after diagnosis must also be considered.

There are reports that diagnosis has become more common than in the past in Asia, including Korea, but because of differences between countries in health care systems, data collection methods, and access to diagnosis, caution is needed in making simple comparisons. In summary, it is helpful to understand it as "often beginning in young adults, more common in women, varying greatly by region, and recently showing an overall increase in the number of patients."

Pathogenesis

The key point is that "immune cells attack the myelin and nerves of the central nervous system." Myelin, like the insulation on an electric wire, helps nerve signals travel quickly and accurately; when myelin is damaged by inflammation, signal transmission slows or is interrupted, causing symptoms such as decreased vision, abnormal sensation, muscle weakness, dizziness, and unsteady walking. When the inflammation subsides, there is partial recovery, but with repeated episodes, recovery may be incomplete or damage to the nerves themselves (axons) may accumulate, leaving disability.

Both T cells and B cells are known to be involved in the immune response. In particular, B cells can influence lesion formation by producing antibodies and secreting substances that regulate inflammation, and the observation of oligoclonal bands in the cerebrospinal fluid is explained as a trace of this immune response.

The brain and spinal cord have a "gatekeeping system" called the blood-brain barrier, and when this barrier loosens during inflammation, immune cells can enter the brain more easily and lesions can become more active. Contrast-enhancing lesions seen on MRI often suggest active lesions associated with such barrier changes. In recent research, how infection, gut microbiota, and lifestyle affect immune balance and the persistence of inflammation is being studied broadly.

Symptoms

Symptoms vary greatly depending on where the lesions occur, and multiple sclerosis cannot be determined "from a single symptom alone." Typically, however, decreased vision or eye pain (optic neuritis), numbness and decreased sensation in the limbs, weakness in one or both limbs, dizziness and balance problems, and a feeling of staggering when walking can appear suddenly one day or over several days. Fatigue is very common and can greatly interfere with daily life.

When vision becomes blurry or colors look faded, and pain accompanies eye movement, the possibility of optic neuritis is considered. A sensation like electricity running down the spine when bending the neck forward (Lhermitte's sign) can also appear in some people. A phenomenon in which existing symptoms temporarily worsen in a hot environment or with fever has also been reported.

Autonomic nervous system symptoms such as urinary problems (urgency, frequency, urinary retention) or constipation, as well as muscle stiffness and cramps, pain, and sexual dysfunction, can also commonly accompany the disease. In addition, some people may have decreased concentration, slowed processing speed, and emotional problems such as depression and anxiety. Many cases take a form in which symptoms appear and then improve (relapsing-remitting), but some show a progressive course that gradually worsens over time, so monitoring the course is important.

Signs

Signs mean objective findings that medical staff confirm through examination. Typically, in unilateral optic neuritis, an abnormal pupillary response (RAPD) or visual field defect can be confirmed, and upper motor neuron signs such as hyperreflexia and the Babinski sign can appear along with muscle weakness. When the cerebellum or brainstem is affected, ataxia (a feeling that the hands and feet shake or cannot hit a target accurately), nystagmus (eye tremor), and dysarthria (slurred pronunciation) may be observed.

On sensory examination, decreased sensation in specific areas or a "sensory level" may be found, and balance problems may become apparent on gait testing. The pattern of these neurological deficits recurring at different times and in different locations is an important clue called "dissemination in time and space."

As imaging signs, multiple demyelinating lesions are seen on MRI, and they are known to tend to be distributed in periventricular, juxtacortical, infratentorial, and spinal cord locations. Active lesions may appear as contrast-enhancing, and when mixed with old lesions, they provide a clue to change over time. However, white spots on MRI can also arise from other causes (such as vascular changes), so imaging must always be interpreted together with the clinical picture.

Screening

Multiple sclerosis is not a disease for which "screening of the entire asymptomatic population" has been established, as it has for hypertension or diabetes. Instead, recognizing warning signs when specific symptoms appear and promptly connecting to a neurological evaluation is effectively closest to screening. The warning signs that are helpful for the general public to know are as follows.

First, cases in which decreased vision and eye pain that are hard to explain persist for several days or more, or begin on one side and recur even after recovery. Second, cases in which numbness, decreased sensation, or weakness in the limbs recurs more than once or appears in changing locations. Third, cases in which dizziness and balance problems are pronounced but not explained by an ear disorder, or symptoms of unsteady walking recur.

In such cases, the possibility of a central nervous system problem is first evaluated through a neurological examination, and if necessary, lesions are confirmed by MRI. In recent research, studies are underway on whether specific imaging markers on MRI (e.g., the central vein sign) can help distinguish multiple sclerosis from other diseases that cause white spots, but this is not yet at the stage of being used as standard screening in all medical institutions. Therefore, the current realistic approach can be summarized as "suspect early based on symptoms and confirm quickly with appropriate tests."

Diagnosis

Diagnosis is usually made by combining "symptoms" and "tests." The key concept is to prove or strongly suggest that the lesions differ in time (past and present lesions are mixed, or new lesions appear on follow-up) and occur in multiple locations in space. For this, the history-taking carefully checks for the presence of similar past episodes (decreased vision, abnormal sensation, muscle weakness, etc.), when they occurred, and whether there was recovery.

The most important pillar of testing is MRI of the brain and spinal cord. It is examined whether there are lesions in typical locations, whether contrast-enhancing lesions (active) and non-enhancing lesions (old) are present together, and whether new lesions are added on follow-up MRI. When necessary, a cerebrospinal fluid test is performed to confirm traces of chronic inflammation such as oligoclonal bands. In addition, visual evoked potentials (VEP) can be used as a supplementary test that indirectly shows optic nerve damage that was not noticed visually.

Another important part of diagnosis is "ruling out other diseases." Other inflammatory demyelinating diseases such as neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disease (MOGAD), as well as infection, vasculitis, vitamin B12 deficiency, and sarcoidosis, can produce similar symptoms. Therefore, after confirming that there is no other cause through the clinical picture, MRI pattern, and blood and cerebrospinal fluid tests, the internationally used diagnostic criteria (McDonald criteria) are applied to make the final diagnosis.

Treatment

Treatment is easy to think of in three broad parts: "treatment of acute exacerbations (relapses)," "treatment that slows relapses and progression of the disease," and "symptom control and rehabilitation." When an acute relapse is suspected, high-dose steroids are commonly used and can help symptoms subside more quickly. In some situations where the response to steroids is very poor and symptoms are severe, treatments such as plasma exchange may also be considered.

Disease-modifying therapy aims to lower the frequency of relapses, reduce MRI lesion activity, and slow the accumulation of disability over the long term. There are many options, ranging from injectables (interferon beta, glatiramer acetate) and oral drugs (fumarates, S1P receptor modulators, etc.) to B-cell-targeted antibody therapies. Which treatment to choose is decided by considering disease activity, MRI findings, pregnancy plans, infection risk, coexisting conditions, and the feasibility of monitoring together. In recent research, discussion continues that a strategy of using more potent treatments from the early stage may help long-term prognosis in some patients.

Symptom control determines the patient's quality of life. For fatigue, spasticity, pain, depression, urinary problems, and walking difficulties, exercise and physical therapy, occupational therapy, walking aids, cognitive rehabilitation, and other measures are applied in a tailored way along with drug treatment. Because multiple sclerosis differs from person to person, it is difficult to solve everything with "a single treatment package," so in the long term, multidisciplinary management in which neurological care, rehabilitation, and lifestyle adjustment go together is important.

Prognosis

Prognosis varies greatly between individuals. Many people begin with the relapsing-remitting type, and symptoms can recover to a considerable extent after a relapse. However, over time some may move into a stage in which function gradually declines even between relapses (secondary progressive), and there is also a primary progressive type that gradually worsens from the beginning. Factors cited as determining prognosis include age at onset, type of initial symptoms, the amount and location of lesions on the initial MRI (especially spinal cord lesions), the degree of initial disability, relapse frequency, and the timing of the start of treatment.

With the development of disease-modifying therapy, the overall prognosis is assessed to have improved compared with the past. Recent research shows that there can be "silent progression," in which brain atrophy or microscopic damage progresses even when the disease appears clinically quiet, so rather than feeling reassured simply because there are no relapses, an approach that continuously checks disease activity through symptoms, examination, MRI, and so on is emphasized.

Beyond multiple sclerosis itself, how well accompanying problems such as fatigue, depression, pain, and urinary dysfunction are managed has a major impact on actual daily function and keeping one's job. Therefore, the prognosis as experienced can differ greatly depending not only on "how much the disease progresses" but also on "how well symptoms are controlled and how consistently rehabilitation is carried out."

Prevention

At present, there is no "single proven method" that reliably prevents multiple sclerosis. However, because there are risk factors with associations repeatedly observed in research, a lifestyle that lowers risk as much as possible can be recommended. Most notably, quitting smoking is the most realistic recommendation with relatively consistent evidence. Because there are studies showing that sunlight exposure and vitamin D are associated with risk, there is discussion that correcting a confirmed deficiency to an appropriate level may help, but it is difficult to conclude that supplements alone prevent the disease.

Because there are reports that obesity in adolescence and young adulthood raises the risk, weight management and regular exercise are meaningful not only for overall health but also in terms of managing a potential risk factor. Preventing infection is important as part of general health care, but it is difficult to say that completely avoiding a particular infection can prevent multiple sclerosis.

In recent research, there is growing interest in whether an Epstein-Barr virus vaccine or antiviral strategies could contribute to the prevention of multiple sclerosis in the long term. However, this is still at the research stage, and at present the prevention measures that the general public can practice can be summarized as "avoiding smoking, maintaining a healthy weight and activity level, correcting vitamin D deficiency in consultation with medical staff if present, and being evaluated early when suspicious symptoms occur."

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.